文章基本信息

标题：Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
本地全文：下载
作者：Xiaoming Jia ; Stephanie Koh ; Mahmoud Al Rifai 等
期刊名称：Vascular Health and Risk Management
印刷版ISSN：1176-6344
电子版ISSN：1178-2048
出版年度：2020
卷号：16
页码：1-10
DOI：10.2147/VHRM.S210149
出版社：Dove Medical Press Ltd
摘要：Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.
关键词：omega-3 fatty acids; icosapent ethyl; eicosapentaneoic acid; cardiovascular outcome